•Semaglutide's patent expired on March 20, allowing Indian pharma majors like Sun Pharma, Dr Reddy’s, and Zydus to launch generic versions.
•Generic entry is expected to cause a 50-70% price drop, making the drug more accessible for diabetic and obese patients in India.
•Experts highlight Semaglutide as a "game-changing, disease-modifying drug" for its benefits beyond glucose control, including weight loss and cardiovascular protection.
•Medical professionals warn against unsupervised use due to potential side effects and the drug's complex nature, emphasizing prescription by specialists.
•Novo Nordisk is defending its market share by lowering prices, using legal means, and partnering with companies like Abbott India for distribution of second brands.
